Hongtao Tan,
Lingling Liu,
Junxian Chen 
,
Yunchang Zhong,
Yicong Li,
Yiqun Li,
Wei Zhang
For correspondence:- Junxian Chen Email: Junx_ch@sina.cn Tel:+862036588233
Accepted: 5 January 2022 Published: 31 January 2022
Citation: Tan H, Liu L, Chen J, Zhong Y, Li Y, Li Y, et al. Yiqi Huoxue Huatan formula attenuates inflammation in chronic obstructive pulmonary disease by suppressing the activation of PI3K/AKT and NF-κB signaling pathways. Trop J Pharm Res 2022; 21(1):45-52 doi: 10.4314/tjpr.v21i1.8
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To explore the mechanism with which Yiqi Huoxue Huatan formula regulates inflammation in chronic obstructive pulmonary disease (COPD).
Methods: COPD rat models (n=60) were procured and administered with prednisone and Yiqi Huoxue Huatan formula. Histological examination of lung tissues was carried out and bronchoalveolar fluid was collected for further analysis. In addition, quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to evaluate the ex
Results: The results showed that Yiqi Huoxue Huatan formula relieved the lung inflammation and helped to preserve alveolar structure, and its anti-inflammatory efficacy was superior to prednisone. Moreover, it significantly improved pulmonary function in COPD rats. This formula was shown to repress the activity of both PI3K/AKT and NF-κB signaling pathways.
Conclusion: Yiqi Huoxue Huatan formula may be effective in treating COPD by attenuating local inflammation and improving pulmonary function.
Archives
News Updates
Fulltext in PDF